Sweden Diabetes market is increasing and continues to grow. In Sweden, diabetes prevalence has been projected to rise in future in adults 20–79 years, as a consequence of the ageing population. It is currently one of the most significant emergencies in terms of global health and shows an increasing prevalence in Sweden. The health care system of Sweden has taken a heavy toll due to diabetes, and this could be due to the associated direct costs required for medical management. But also because of indirect costs with regards to loss of productivity, early and premature mortality, and at the same time, the damage to a nations’ gross domestic product (GDP). According to Renub Research report, Sweden Diabetes Market is expected to be USD 5.82 Billion by the end of the year 2025.
In this report, Sweden Diabetic market is divided into four categories; GM, SMBG, Insulin Pump and Insulin Pen. All the four insulin delivery devices categories mentioned above are growing year on year. According to our analysis, the number of cases of diabetes will increase between 2011 and 2026. This increase is due to the change in population size and the rise in the number of old age population.
Companies Imitative in Sweden Diabetes Care Segment
Sept 2018, Liva’s digital health program rolled out in the Sweden region. Liva Healthcare; introduces the innovative digital health coaching platform for scalable lifestyle and disease management.
MAY 2020, Blighter’s Actiste service, for people living with insulin-treated diabetes, is available to consumers. Customers can easily sign up directly at the Artiste website.
Renub Research report titled “Sweden Diabetes Market & Forecast, By Self Monitoring Blood Glucose Device Analysis (SMBG Market by, Test Strips, Lancet, Meter, Blood Glucose Device Users & Reimbursement) Continuous Glucose Monitoring (CGM Market by Components, Glucose Sensor, Transmitter, CGM User, Reimbursement), Insulin Pen Types (Disposable, Reusable & Smart Insulin Pen, Needle Market, Reimbursement Policies), Insulin Pump Market, (User and Reimbursement) Companies (Insulet Corporation, B. Braun Melsungen AG, LifeScan Inc., Artsana S.p.A, BD, Novo Nordisk A/S, Owen Mumford Ltd, Ypsomed AG, Medtronic, Eli Lilly and Company, Abbott Laboratories, Dexcom Inc and Roche)” provides a complete analysis of Germany Insulin Devices Market.
About Company:
Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises of major players in Life Sciences, Information Technology, Telecom, Financial Services (Banking, Insurance), Energy, Retail, Manufacturing, Automotive, and Social sector. Our clients rely on our market analysis and data to make informed knowledgeable decisions. We are regarded as one of the best providers of knowledge. Our pertinent analysis helps consultants, bankers and executives to make informed and correct decisions.
Contact Us:
Renub Research
Phone No: +1 678-302-0700 (USA) | +91-120-421-9822 (IND)
Email: info@renub.com
Follow on Linkedin: https://www.linkedin.com/company/renub-research
Comments